Lucid Diagnostics to be deconsolidated from PAVmeds financial statements
| LUCD Stock | USD 1.59 0.26 19.55% |
About 54% of Lucid Diagnostics' shareholders are presently thinking to get in. The analysis of overall sentiment of trading Lucid Diagnostics stock suggests that some investors are interested at this time. The current market sentiment, together with Lucid Diagnostics' historical and current headlines, can help investors time the market. In addition, many technical investors use Lucid Diagnostics stock news signals to limit their universe of possible portfolio assets.
PAVmed announces deconsolidation of Lucid Diagnostics to regain compliance with Nasdaq listing requirements, boosting stockholders equity.
Read at seekingalpha.com
 |
Lucid Diagnostics Fundamental Analysis
We analyze Lucid Diagnostics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lucid Diagnostics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lucid Diagnostics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Gross Profit
Gross Profit Comparative Analysis
Lucid Diagnostics is currently under evaluation in gross profit category among its peers. Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Lucid Diagnostics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Lucid Diagnostics stock to make a market-neutral strategy. Peer analysis of Lucid Diagnostics could also be used in its relative valuation, which is a method of valuing Lucid Diagnostics by comparing valuation metrics with similar companies.
Peers
Lucid Diagnostics Related Equities
| XAIR | Beyond Air | 5.56 | ||||
| CLPT | Clearpoint Neuro | 5.47 | ||||
| LIVN | LivaNova PLC | 5.11 | ||||
| CVRX | CVRx | 4.35 | ||||
| OFIX | Orthofix Medical | 3.51 | ||||
| KIDS | Orthopediatrics Corp | 1.39 | ||||
| SRDX | SurModics | 0.38 | ||||
| ITGR | Integer Holdings | 0.13 | ||||
| LUNG | Pulmonx Corp | 0.64 | ||||
| IRMD | Iradimed | 2.28 | ||||
| ELMD | Electromed | 3.44 | ||||
| NPCE | Neuropace | 28.39 |
Complementary Tools for Lucid Stock analysis
When running Lucid Diagnostics' price analysis, check to measure Lucid Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lucid Diagnostics is operating at the current time. Most of Lucid Diagnostics' value examination focuses on studying past and present price action to predict the probability of Lucid Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lucid Diagnostics' price. Additionally, you may evaluate how the addition of Lucid Diagnostics to your portfolios can decrease your overall portfolio volatility.
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |